This product is designed and manufactured by Transgene using its proprietary platform myvac (*1) and integrating neoantigens selected by NEC's Neoantigen Prediction System.
TG4050 capitalises on the tremendous progress in the field of artificial intelligence and on advances in genome sequencing to create an individualized immunotherapy, targeted to mutated antigens identified by sequencing and predicted to be relevant target by the NEC's algorithm.
Transgene will be responsible for the clinical development and will sponsor two clinical studies starting in H2 2019, cinlduing a study in ovarian cancer patients after first line surgery and chemotherapy and a study in head and neck cancer patient after surgery and radiation therapy.
These studies, which will be co-financed by Transgene and NEC, will evaluate safety and immunogenicity of TG4050 and, pave the way for combination studies with different classes of therapies.
myvac is a viral vector based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors.
The myvac-derived products are designed to stimulate the patient's immune system, recognize and destroy tumors using the patient's own cancer specific genetic mutations.
Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorisation know-how and unique manufacturing capabilities.
NEC's neoantigen prediction utilizes its proprietary AI, such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets.
NEC comprehensively evaluates the candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction.
These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.
Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases.
Transgene's programmes utilise viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.
The company's lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers.
The company has several other programmes in clinical development, including TG1050 (a therapeutic vaccine for the treatment of chronic hepatitis B) and TG6002 (an oncolytic virus for the treatment of solid tumors).
With its proprietary Invir.IO, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses.
myvac, an individualised MVA-based immunotherapy platform designed to integrate neoantigens, completes this innovative research portfolio.
TG4050, the first candidate selected from the myvac platform, will enter the clinic for the treatment of ovarian cancer and head and neck cancer.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial